MCL Literature Feed

888 papers on mantle cell lymphoma from PubMed. Updated daily.

ADC BCL2i BTKi CAR-T CDK4/6i CNS MRD PI3Ki TP53-mutated biomarkers bispecific blastoid case report chemotherapy consolidation elderly epidemiology frontline genomics guidelines

Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.

Natalia Rotter, Markus Raderer, Agnes List et al.·EJHaem·Aug 1, 2026

Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.

Fen Zhu, Jing Wang, Christine E Ryan et al.·Blood neoplasia·Aug 1, 2026

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

Matthew J Frigault, Richard T Maziarz, Theresa Amoloja et al.·Transplantation and cellular therapy·Jul 31, 2026

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Sean McKeague, Pietro R Di Ciaccio, Steven Tran et al.·Internal medicine journal·Jul 30, 2026

Surveying the Genomic Landscape of Mantle Cell Lymphoma Indicates the Importance of Multimodal Genomic and Transcriptomic Exploration.

Charlz Nithin Jerold, Brian Li, Matthew Mosior et al.·medRxiv : the preprint server for health sciences·Jul 29, 2026

Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry.

Jonas Moritz Huhn, Mona Hashemian, Martina Kinzig et al.·Journal of pharmaceutical and biomedical analysis·Jul 29, 2026

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.

Schayan Yousefian, Maria-Luisa Schubert, Anna Rita Minafra et al.·Nature communications·Jul 29, 2026

Evolution of mantle cell lymphoma therapy: advancing frontline precision.

Shijia Li, Richard E Champlin, Michael L Wang·Trends in cancer·Jul 28, 2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Riccardo Moia, Mohammad Almasri, Maria Elena Carazzolo et al.·Blood advances·Jul 24, 2026

Invasive pneumococcal disease unmasks monoclonal immunoglobulins and antibody deficiencies: a multicenter prospective study in adults.

Tor Härnqvist, Karin Bergman, Åsa Mellgren et al.·Scientific reports·Jul 24, 2026

Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.

Satishkumar Singh, Yuanfeng Wang, Anuvrat Sircar et al.·Biomarker research·Jul 24, 2026

The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas.

Junya Kuroda, Taku Tsukamoto, Yuji Shimura·Expert opinion on therapeutic targets·Jul 23, 2026

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

Ferran Araujo-Ayala, Maria Ros, Raluca Alexandru et al.·Blood·Jul 22, 2026

Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.

Anna M Mc Laughlin, Martin Bergstrand, Ana Ruiz-Garcia et al.·Clinical pharmacology and therapeutics·Jul 21, 2026

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.

Victor M Samperio, Moza Hamoud, Ifeoma Ike et al.·European journal of haematology·Jul 21, 2026

Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

·The Medical letter on drugs and therapeutics·Jul 20, 2026

Identification of E3 Ubiquitin Ligases Associated with Survival in Soft Tissue Sarcomas.

Zackary Bender, Hannah C Beird, Peter Larsen et al.·International journal of molecular sciences·Jul 17, 2026

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Robert Puckrin, Diego Villa, Isabelle Fleury et al.·Current oncology (Toronto, Ont.)·Jul 17, 2026

Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints.

Amy Clark, Sophie Van Tomme, Lucinda Hetherington et al.·Current oncology (Toronto, Ont.)·Jul 17, 2026

Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial).

Sebastian Giebel, Anna Czyż, Iwona Hus et al.·Annals of hematology·Jul 17, 2026

Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.

Jonas Wißkirchen, Nora S Rogmann, Michael Greiling et al.·Annals of hematology·Jul 16, 2026

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Marco Ladetto, Katja Gutmair, Rita Tavarozzi et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology·Jul 14, 2026

Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Toby A Eyre, Yuqin Song, Olivier Hermine et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology·Jul 14, 2026

Genetically Predicted Gut Microbiota and Lymphoma Risk: A Mendelian Randomization Study.

Danhua Li, Tongfei Zhou, Meng Liu et al.·Current pharmaceutical biotechnology·Jul 13, 2026

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

Michael Wang, Wojciech Jurczak, Marek Trneny et al.·British journal of haematology·Jul 12, 2026

Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Expanding the Horizon of CAR-T Cell Therapy: Present Obstacles and New Strategies for Future CARs in Solid Tumors.

Qasim Javed, Shoaib Majeed, Adnan Shahid et al.·Anti-cancer agents in medicinal chemistry·Jul 10, 2026

Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.

Yixin Yao, Yue Fei, Fangfang Yan et al.·Leukemia·Jul 9, 2026

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Peter Dreger, Gloria Iacoboni, Stephen Robinson et al.·Bone marrow transplantation·Jul 9, 2026

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Jonas Lippl, Sarah Reinke, Karoline Koch et al.·Leukemia·Jul 7, 2026

Stereoselective Covalent Targeting of BTK(C481S) and Kinases with β-Lactone Electrophiles.

Celine D Wang, Polina E Barzova, Julian Robles et al.·bioRxiv : the preprint server for biology·Jul 6, 2026

← PreviousPage 2 of 30Next →